Literature DB >> 10782907

Suppression of hepatic lesions in a murine graft-versus-host reaction by antibodies against adhesion molecules.

S Itoh1, Y Matsuzaki, T Kimura, R Unno, T Ikegami, J Shoda, M Doy, M Fujiwara, N Tanaka.   

Abstract

BACKGROUND/AIMS: The injection of parental CD4+ T cells into major histocompatibility complex (MHC) class II disparate F1 hybrid mice induced an autoimmune graft-versus-host reaction (GVHR) which is analogous to autoimmune liver diseases. The interaction of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and very late antigen-4 (VLA-4) has been known to be profoundly involved in the trafficking of lymphocytes into the inflammatory tissues. The aim of this study was to clarify the role of VLA4 or VCAM-1 in the development of GVHR-induced hepatic lesions in our model.
METHODS: B6 T spleen cells were injected into (B6.C-H-2bm12xB6) F1 mice intravenously. Anti-VLA-4 mAbs and/or anti-VCAM-1 mAbs were injected intraperitoneally at a dose of 2.5 mg/kg of each mAbs per body weight of mouse. We examined the changes in GVHR-induced hepatic lesions, serum levels of antimitochondrial antibodies (AMA) and cytokine mRNA expressions of liver-infiltrating lymphocytes using H.E. and immunohistochemical staining, enzyme-linked immunosorbent assay (ELISA), and reverse transcription-polymerase chain reaction (RT-PCR), respectively.
RESULTS: Hepatic lesions of anti-VLA-4 mAbs-treated mice were inhibited compared with those of GVHR mice. However, the administration of mAbs did not interfere with the induction of splenomegaly, the invasion of CD4+, CD8+, B220+, or Mac-1+ cells around bile ducts, nor the production of AMA. Liver-infiltrating CD4+ T cells obtained from these treated mice did not alter the expression of T helper (Th)1 and Th2 cytokine mRNA.
CONCLUSION: The results suggest that treatment with antibodies against these adhesion molecules could inhibit the infiltration of lymphocytes without affecting the Th1/Th2 balance. The blockade of VLA-4-mediated cell infiltration into the liver in this model may have a possible novel therapeutic role of VLA-4 mAbs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782907     DOI: 10.1016/s0168-8278(00)80220-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  4 in total

Review 1.  Leukocyte migration and graft-versus-host disease.

Authors:  Christian A Wysocki; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

Review 2.  Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?

Authors:  Roberto González-Amaro; María Mittelbrunn; Francisco Sánchez-Madrid
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

3.  Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease.

Authors:  Laurent Burnier; François Saller; Linda Kadi; Anne C Brisset; Rocco Sugamele; Lucie Baudino; Françoise Bono; Jean-Marc Herbert; Peter Carmeliet; Marc Schapira; Shozo Izui; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

4.  Novel expression of vascular cell adhesion molecule-1 (CD106) by squamous epithelium in experimental acute graft-versus-host disease.

Authors:  Judith C Kim; Diana Whitaker-Menezes; Masatoshi Deguchi; Brigette S Adair; Robert Korngold; George F Murphy
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.